ClinicalTrials.Veeva

Menu
C

Carolina Research Center, Inc. | Shelby, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3502970
Ensifentrine
Astegolimab
Orforglipron
EDP-235
Ranolazine
K-304
Elismetrep
Selonsertib
Polypill

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 30 total trials
Locations recently updated

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus...

Enrolling
Uncontrolled Gout
Drug: Pegloticase
Drug: Methotrexate

This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.

Not yet enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep

This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to p...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Glycopyrrolate 21.25 mcg
Drug: Ensifentrine 3 mg

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron work...

Enrolling
Osteoarthritis
Drug: Orforglipron
Drug: Placebo

This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with plac...

Enrolling
Migraine
Drug: Placebo
Drug: Elismetrep

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling
Chronic Obstructive Pulmonary Disease
Drug: Astegolimab

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Active, not recruiting
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide

Trial sponsors

Pfizer logo
Gilead Sciences logo
Lilly logo
Amgen logo
Enanta Pharmaceuticals logo
K
B
Boehringer Ingelheim logo
Genentech logo
Kowa logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems